9.19

1.32% 0.12

Amicus Therapeutics Inc (FOLD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt FOLD? Forum Prognose

Schlusskurs vom Vortag:

$9.07

Offen:

$9.15

24-Stunden-Volumen:

2.57M

Relative Volume:

1.14

Marktkapitalisierung:

$2.76B

Einnahmen:

$493.67M

Nettoeinkommen (Verlust:

$-104.69M

KGV:

-27.03

EPS:

-0.34

Netto-Cashflow:

$-31.51M

1W Leistung:

-5.94%

1M Leistung:

-3.36%

6M Leistung:

-23.99%

1J Leistung:

-32.23%

1-Tages-Spanne:

$9.02

$9.26

1-Wochen-Bereich:

$9.02

$10.00

52-Wochen-Spanne:

$8.785

$14.02

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Firmenname

Amicus Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(609) 662-2000

Adresse

47 HULFISH STREET, PRINCETON, NJ

Mitarbeiter

499

Twitter

@amicusrx1

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

FOLD's Discussions on Twitter

Vergleichen Sie FOLD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FOLD Amicus Therapeutics Inc	9.19	2.76B	493.67M	-104.69M	-31.51M	-0.34
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-09-06	Eingeleitet	Jefferies	Buy
2024-05-30	Eingeleitet	Wells Fargo	Overweight
2024-05-14	Hochstufung	Guggenheim	Neutral → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-04-13	Fortgesetzt	Goldman	Neutral
2022-01-14	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-15	Hochstufung	Stifel	Hold → Buy
2021-09-30	Hochstufung	JP Morgan	Neutral → Overweight
2021-07-19	Fortgesetzt	BTIG Research	Buy
2021-05-27	Eingeleitet	Needham	Hold
2021-05-21	Eingeleitet	UBS	Buy
2021-04-14	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2021-03-02	Eingeleitet	Stifel	Hold
2021-02-12	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-28	Fortgesetzt	Cantor Fitzgerald	Overweight
2020-12-10	Herabstufung	Citigroup	Buy → Neutral
2020-11-11	Eingeleitet	Berenberg	Hold
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-02-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-11-12	Bestätigt	H.C. Wainwright	Buy
2019-06-17	Eingeleitet	H.C. Wainwright	Buy
2019-06-05	Bestätigt	Cantor Fitzgerald	Overweight
2019-04-05	Eingeleitet	Janney	Buy
2019-01-30	Eingeleitet	Cantor Fitzgerald	Overweight
2018-10-29	Eingeleitet	Citigroup	Neutral
2018-08-17	Herabstufung	Chardan Capital Markets	Buy → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral
2017-09-13	Bestätigt	Chardan Capital Markets	Buy
2017-08-10	Bestätigt	Chardan Capital Markets	Buy
2017-01-24	Hochstufung	Robert W. Baird	Neutral → Outperform
2016-05-18	Eingeleitet	BofA/Merrill	Buy
2016-04-14	Eingeleitet	Robert W. Baird	Neutral
2016-04-12	Bestätigt	Chardan Capital Markets	Buy
2015-09-16	Herabstufung	Chardan Capital Markets	Buy → Neutral
2015-06-16	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten

07:29 AM

Transcend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

07:29 AM

Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia

Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN

Feb 21, 2025

Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India

Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales - Investing.com India

Feb 21, 2025

Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com

Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat

Feb 21, 2025

Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.

Feb 21, 2025

Wells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat

Feb 21, 2025

Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat

Feb 21, 2025

Amicus Therapeutics (FOLD) Expected to Announce Earnings on Wednesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN

Feb 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat

Feb 20, 2025

Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat

Feb 20, 2025

Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN

Feb 20, 2025

Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Feb 20, 2025

Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net

Feb 20, 2025

Feb 19, 2025